Jam

Prime Success L.P., holding an 8% stake in Sinovac Biotech, issued a statement criticizing the company’s upcoming shareholder meeting on July 8, 2025, and the actions of the current board (“1Globe Activist Board”). Prime Success, a large shareholder, accuses the board of misleading statements regarding dividend distribution timing and manipulating facts. They advocate for a dividend payout before the meeting and urge shareholders to vote for a new board nominated by SAIF, emphasizing the critical need for competent leadership focused on the company’s long-term success.

West Coast Community Bancorp announced the results of its annual director election, with shareholders strongly approving management’s slate. High voter turnout (74.41%) and overwhelming support, with percentages ranging from 86.34% to 96.19% for individual directors, signify confidence in the bank’s strategic direction. Shareholders also ratified the appointment of Crowe LLP as the independent auditor with 99.85% approval.

Avino Silver & Gold Mines Ltd. renewed its At-The-Market (ATM) equity program, allowing for the distribution of up to $40 million in common shares through a sales agreement. This provides Avino with strategic financial flexibility, enabling share sales at prevailing market prices via the NYSE American and other markets. The company will pay commissions up to 3.0% on gross proceeds, though there’s no guarantee of sales. The ATM program, approved conditionally by the Toronto Stock Exchange, aims to support Avino’s financial planning and growth.

Search Minerals (TSXV: SMY) announced the resumption of trading on June 16, 2025, and a share consolidation (10:1) effective June 17, 2025. The company focuses on critical rare earth elements like CREE, Zr, and Hf, with assets in Labrador’s Port Hope Simpson-St. Lewis and Red Wine districts, including ready-to-drill prospects. This release includes forward-looking statements about potential risks and uncertainties.

Houston American Energy Corp. (HUSA) announced unusual trading activity in its stock without identifying a specific cause. The company, focused on oil and gas exploration in the U.S. Permian Basin and Louisiana, warns of market volatility and forward-looking statements subject to risks like market fluctuations, potential impacts within the energy sector, and operational challenges. Investors should consider SEC filings for detailed risk factors impacting future results.

Wallbridge Mining’s Annual and Special Meeting on June 12, 2025, saw significant shareholder representation and strong support for all resolutions. Shareholders elected six directors, including Brian Penny and Janet Wilkinson, with high approval ratings. KPMG LLP was reappointed as auditor. The approval of the Omnibus Long Term Incentive Plan further highlights shareholder confidence and commitment to long-term value creation.

Abbott announced its 406th consecutive quarterly dividend of $0.59 per share, payable August 15, 2025. This marks 53 consecutive years of dividend increases, highlighting Abbott’s financial strength and its inclusion in the S&P 500 Dividend Aristocrats Index. The consistent payouts, starting in 1924, underscore the company’s commitment to shareholder value.

RedCloud Holdings (RCT) will attend the ROTH 15th Annual London Conference from June 24-26 at the Four Seasons Hotel London. CEO Justin Floyd will meet with institutional investors to discuss RedCloud’s platform, which streamlines FMCG trade by providing data access to brands, distributors, and retailers, utilizing AI for B2B decision-making. The invitation-only conference, organized by investment bank ROTH, features intimate meetings for in-depth company insights.

Aurania Resources announced its shareholders approved all proposals at the June 12, 2025 Annual and Special Meeting, including financial statements and director elections. The company clarified the ARCOM fee structure from its June 11, 2025 press release. Aurania continues exploration for precious metals and copper in South America, with a focus on its Lost Cities – Cutucu Project in Ecuador. Further details are available on the company’s website and SEDAR+.

RetinalGenix Technologies Inc. has appointed Dr. Taimour Langaee as a scientific advisor to advance its precision medicine initiatives. Dr. Langaee, an expert in pharmacogenomics, will lead efforts on the company’s DNA GPS Pharmacogenetics platform. This platform aims to personalize treatment pathways for retinal and systemic diseases by analyzing genetic data and linking eye diseases to genetic variations, furthering RetinalGenix’s commitment to early disease detection through advanced retinal imaging.